Xenazine ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 2 |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02509793 (ClinicalTrials.gov) | August 1, 2018 | 24/7/2015 | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) | Huntington's Disease | Drug: Tetrabenazine | William Ondo, MD | H. Lundbeck A/S | Recruiting | 18 Years | 80 Years | All | 20 | Phase 4 | United States |
| 2 | NCT00632645 (ClinicalTrials.gov) | April 2009 | 29/2/2008 | Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride | Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study. | Huntington Disease | Drug: Olanzapine;Drug: Xenazine;Drug: Tiapridal | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | All | 180 | Phase 3 | France |